Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 23, 2026.
|Videos|December 27, 2022
Key Points for the Management of Multiple Sclerosis
Stephen Krieger, MD; Daniel Bandari, MD, MS; Bruce Hughes, MD; Mitzi Williams, MD; and Heidi Crayton, MD, provide key takeaways for the treatment of patients with multiple sclerosis.
Advertisement
Advertisement
Stephen Krieger, MD: Well, speaking of key points coming from you, I want to come around and ask you each for a takeaway, a key point, either from ECTRIMS [European Committee for Treatment and Research in Multiple Sclerosis annual meeting] or just something that you were thinking about at this point, fall of 2022, in MS [multiple sclerosis] care. Dr Hughes, do you want to go first and give a closing takeaway point?
Related to this article
A phase 2 trial found liposomal mitoxantrone hydrochloride had an acceptable safety profile and a potential trend toward fewer relapses in neuromyelitis optica spectrum disorder.
The phase 2 FENerations1 study is an open-label, single-arm, small-scale study evaluating fenebrutinib dosing in 8 to 12 children and adolescents with relapsing MS.
Data from the real-world, CONFIDENCE study found switching from intravenous to subcutaneous ocrelizumab was well tolerated in patients with relapsing and primary progressive MS.
Open-label extension data showed that disability trends observed with vidofludimus calcium during the double-blind period of the phase 2 CALLIPER trial persisted with continued treatment in progressive MS.
Early phase 1 data in 3 patients suggest CTA313, an allogeneic CD19/BCMA CAR-T, may stabilize disability with a manageable safety profile in progressive MS.
One-year data from the phase 3 AQUARELLE study found that divozilimab, an anti-CD20 antibody, reduced relapse risk in patients with neuromyelitis optica spectrum disorder.
The chief research and medical affairs officer at the National MS Society discussed AI-enabled imaging, biomarkers of progression, women's health across the lifespan, and the Society's Campaign to End MS.
Advertisement
Advertisement